Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    GSK PLC logo
    GSK

    GSK PLC

    MaveScore 11 Low model confidence
    Last Price US$52.23 As of Jun 15, 2026
    Market Cap US$221.7b Company size context
    7D Performance 3.12% Past 7 days
    1Y Performance 30.54% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Dec 31, 2025

    167 days old

    Market price date

    Jun 15, 2026

    1 day old

    Coverage

    11/16

    5 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 11 Low confidence

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    11/16 Partial or delayed snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    0/35 Weak

    Financial Strength

    Financial strength needs live profitability and cash-flow fields.

    0/25 Needs Data

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    1/15 Weak

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    5/15 Weak

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    5/10 Mixed

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    GSK PLC Overview

    Industry: Drug Manufacturers General

    Sector: Healthcare

    GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.

    GSK PLC is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review GSK PLC in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    GSK PLC Competitors

    GSK PLC operates in the Drug Manufacturers General industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    GSK PLC

    US$52.23

    US$221.7b

    3.12%

    30.54%